MIRA Stock Forecast 2025-2026
Distance to MIRA Price Targets
MIRA Price Momentum
10 Quality Stocks Worth Considering Now
Researching MIRA Pharmaceuticals (MIRA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MIRA and similar high-potential opportunities.
Latest MIRA Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, MIRA has a neutral consensus with a median price target of $17.75 (ranging from $17.75 to $17.75). The overall analyst rating is Buy (6.0/10). Currently trading at $0.94, the median forecast implies a 1,790.3% upside. This outlook is supported by 0 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MIRA Analyst Ratings
MIRA Price Target Range
Latest MIRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MIRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 30, 2024 | Rodman & Renshaw | Elemer Piros | Buy | Initiates | $17.00 |
| Aug 5, 2024 | Ascendiant Capital | Edward Woo | Buy | Initiates | $11.00 |
Mira Pharmaceuticals Inc. (MIRA) Competitors
The following stocks are similar to MIRA Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Mira Pharmaceuticals Inc. (MIRA) Financial Data
Mira Pharmaceuticals Inc. has a market capitalization of $15.55M with a P/E ratio of -1.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -238.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Mira Pharmaceuticals Inc. (MIRA) Business Model
About Mira Pharmaceuticals Inc.
Develops novel therapeutics for neurological disorders.
Mira Pharmaceuticals generates revenue through the research and development of innovative drugs targeting unmet medical needs in the neurological and neuropsychiatric fields. The company focuses on creating effective treatment options for conditions like anxiety, depression, and cognitive impairments, leveraging advanced drug formulation and delivery technologies.
With a commitment to improving patient quality of life, Mira Pharmaceuticals is positioned to attract interest from investors and healthcare professionals alike due to its potential to introduce groundbreaking therapies. The company plays a significant role in the healthcare industry, contributing to scientific advancements and impacting investment portfolios that prioritize medical innovation.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
0
CEO
Mr. Erez Aminov
Country
United States
IPO Year
2023
Website
mirapharmaceuticals.comMira Pharmaceuticals Inc. (MIRA) Latest News & Analysis
MIRA Pharmaceuticals reported that its oral ketamine analog, Ketamir-2, showed strong efficacy in an animal model of diabetic neuropathy, with some subjects achieving complete symptom reversal.
MIRA Pharmaceuticals' positive results for Ketamir-2 in treating diabetic neuropathy could lead to significant market potential, boosting investor confidence and stock value.
MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
18 days agoMIRA Pharmaceuticals (NASDAQ:MIRA) has begun enrolling subjects in a Phase 1 clinical trial for Ketamir-2, an oral ketamine analog aimed at treating neuropathic pain, at Hadassah Medical Center.
MIRA Pharmaceuticals' Phase 1 trial for Ketamir-2 signals potential advancements in treating neuropathic pain, which could lead to significant market opportunities and impact stock performance.
MIRA Pharmaceuticals plans to acquire SKNY Pharmaceuticals, enhancing its pipeline with SKNY-1, a preclinical oral therapy for obesity and smoking cessation, and receiving a $5M capital infusion.
MIRA's acquisition of SKNY enhances its drug pipeline, targeting major health issues. The capital infusion strengthens its financials, potentially boosting future growth and investor confidence.
MIRA Pharmaceuticals (NASDAQ:MIRA) has developed a topical formulation of Ketamir-2 for localized neuropathic and inflammatory pain, enhancing its pain management offerings beyond the oral version.
MIRA Pharmaceuticals' successful formulation of a topical Ketamir-2 treatment diversifies its pain management portfolio, potentially increasing market share and revenue from innovative therapies.
MIRA Pharmaceuticals (NASDAQ:MIRA) announced the approval of its Phase 1 clinical trial for Ketamir-2, an oral ketamine analog for neuropathic pain, with recruitment starting Q1 2025 in Israel.
The approval of MIRA Pharmaceuticals' Phase 1 trial for Ketamir-2 signals progress in drug development, potentially enhancing the company's valuation and attracting investor interest in the biotech sector.
MIRA Pharmaceuticals (NASDAQ:MIRA) has submitted an IND application to the FDA for Ketamir-2, an oral ketamine analog aimed at treating neuropathic pain, advancing its lead drug candidate.
MIRA Pharmaceuticals' IND application for Ketamir-2 signals potential progress in drug development, which can enhance investor confidence and drive stock performance based on future clinical prospects.
Frequently Asked Questions About MIRA Stock
What is Mira Pharmaceuticals Inc.'s (MIRA) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Mira Pharmaceuticals Inc. (MIRA) has a median price target of $17.75. The highest price target is $17.75 and the lowest is $17.75.
Is MIRA stock a good investment in 2025?
According to current analyst ratings, MIRA has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.94. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MIRA stock?
Wall Street analysts predict MIRA stock could reach $17.75 in the next 12 months. This represents a 1,790.3% increase from the current price of $0.94. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Mira Pharmaceuticals Inc.'s business model?
Mira Pharmaceuticals generates revenue through the research and development of innovative drugs targeting unmet medical needs in the neurological and neuropsychiatric fields. The company focuses on creating effective treatment options for conditions like anxiety, depression, and cognitive impairments, leveraging advanced drug formulation and delivery technologies.
What is the highest forecasted price for MIRA Mira Pharmaceuticals Inc.?
The highest price target for MIRA is $17.75 from at , which represents a 1,790.3% increase from the current price of $0.94.
What is the lowest forecasted price for MIRA Mira Pharmaceuticals Inc.?
The lowest price target for MIRA is $17.75 from at , which represents a 1,790.3% increase from the current price of $0.94.
What is the overall MIRA consensus from analysts for Mira Pharmaceuticals Inc.?
The overall analyst consensus for MIRA is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $17.75.
How accurate are MIRA stock price projections?
Stock price projections, including those for Mira Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.